| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8409973 | Drug Discovery Today | 2018 | 9 Pages |
Abstract
With reduced risk of toxicity and high selectivity, covalent small-molecule kinase inhibitors (CSKIs) have emerged rapidly. Through the lens of structural system pharmacology, here we review this rapid progress by considering design strategies and the challenges and opportunities offered by current CSKIs.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Zheng Zhao, Philip E. Bourne,